Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>CMBI Envisions Recovery in 2H Results for CXO Firms, Favors SINO BIOPHARM/ WUXI XDC
Recommend 24 Positive 22 Negative 14 |
||||
|
||||
|
The MSCI China Healthcare Index has risen by 59.5% YTD, outrunning the MSCI China Index by 24%, according to a report from CMBI. Recently, the pharmaceutical sector has seen a correction, declining around 10% since early October. Believing that some stocks are still undervalued and attractive, CMBI expressed optimism for 3SBIO (01530.HK), GUSHENGTANG (02273.HK), GIANT BIOGENE (02367.HK), WUXI XDC (02268.HK), INNOVENT BIO (01801.HK), and SINO BIOPHARM (01177.HK), all rated as Buy. In CMBI's estimate, with the recovered capital market financing activities, the expanded scale of overseas transactions for innovative drugs, rebounded domestic demand for innovative drug research and development, and the US entering a rate-cutting cycle, a recovery in the results of CXO companies is likely to occur in 2H25. The clinical development of authorized innovative drug pipelines overseas could be the most important catalyst for the innovative drug sector. AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
